Zobrazeno 1 - 10
of 16
pro vyhledávání: '"C J, Refino"'
Publikováno v:
Circulation. 92:3032-3040
Background The thrombolytic properties of a new variant of tissue plasminogen activator (TPA) (T103N, N117Q, KHRR 296-299 AAAA, or TNK-TPA) with longer plasma half-life, greater fibrin specificity, and increased resistance to inhibition by plasminoge
Publikováno v:
Thrombosis and haemostasis. 82(3)
10C12, a human antibody F(ab')2, which specifically binds to the Gla domain of factor IX, interfered with all known coagulation processes that involve factor IX/IXa. These include the function of the intrinsic Xase complex and the activation of zymog
Publikováno v:
Blood. 89(9)
One approach to developing safer and more efficacious agents for the treatment of thrombotic disease involves the design and testing of inhibitors that block specific steps in the coagulation cascade. We describe here the development of a mutant of h
Autor:
G R, Thomas, H, Thibodeaux, C J, Errett, J M, Badillo, D T, Wu, C J, Refino, B A, Keyt, W F, Bennett
Publikováno v:
Thrombosis and haemostasis. 75(6)
Clinical experience suggests that thrombolytic-induced bleeding is associated with systemic activation of the thrombolytic system. Using fibrin specific variants of tissue-type plasminogen activator (t-PA) and making use of the apparent fibrin specif
Publikováno v:
Thrombosis and haemostasis. 75(5)
Multiple clinical trials have proven that thrombolytic therapy is an effective treatment for acute myocardial infarction. Spontaneous intracranial hemorrhage (ICH) occurs in a small percentage of patients as a result of the treatment. The etiology of
Autor:
J Lai, Luis C. Pena, L. Berleau, Bruce Keyt, C Pater, J Ogez, C J Refino, Alice M. Chow, N F Paoni, Hung V. Nguyen
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 91(9)
Current treatment with tissue plasminogen activator (tPA) requires an intravenous infusion (1.5-3 h) because the clearance of tPA from the circulation is rapid (t 1/2 approximately 6 min). We have developed a tPA variant, T103N,N117Q, KHRR(296-299)AA
Autor:
C J, Refino, N F, Paoni, B A, Keyt, C S, Pater, J M, Badillo, F M, Wurm, J, Ogez, W F, Bennett
Publikováno v:
Thrombosis and haemostasis. 70(2)
In the accompanying paper, we reported that the properties of decreased plasma clearance rate, increased fibrin specificity, and resistance to inactivation by PAI-1 could be effectively combined in the t-PA variant T103N, KHRR 296-299 AAAA. In the cu
Autor:
N F, Paoni, B A, Keyt, C J, Refino, A M, Chow, H V, Nguyen, L T, Berleau, J, Badillo, L C, Peña, K, Brady, F M, Wurm
Publikováno v:
Thrombosis and haemostasis. 70(2)
Site directed mutagenesis was used to construct a t-PA variant that contains an additional glycosylation site in the first kringle domain (T103N) combined with a tetra-alanine substitution in the protease domain (KHRR 296-299 AAAA). This combination
Autor:
C. J. Refino, Casey M. Donovan, Peter R. Dallman, Kelvin J.A. Davies, Lester Packer, George A. Brooks
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 246:E535-E543
Three weeks of dietary iron deficiency in weanling rats resulted in anemia (Hb, 3.9 vs. 14.2 g/dl in controls) and decreased oxidative capacities of skeletal muscle (as much as 90% below control values). Whole-animal maximal O2 consumption (VO2max),
Autor:
A Hotchkiss, C J Refino, C K Leonard, J V O'Connor, C Crowley, J McCabe, K Tate, G Nakamura, D Powers, A Levinson, M Mohler, M W Spellman
Publikováno v:
Thrombosis and Haemostasis. 60:255-261
SummaryModification of the carbohydrate structures of recombinant tissue-type plasminogen activator (rt-PA) can increase or decrease its rate of clearance in rabbits. When rt-PA was treated with sodium periodate to oxidize carbohydrate residues, the